donor-derived WT1/PRAME/NY-ESO-1/survivin-specific T-lymphocytes

{
  "id": "MLC-T-ONC-013146",
  "term": "donor-derived WT1/PRAME/NY-ESO-1/survivin-specific T-lymphocytes",
  "field": "Oncology and biomedicine",
  "definition": "Allogeneic T-lymphocytes specifically reactive to the tumor-associated antigens (TAAs) human Wilms tumor protein-1 (WT1), Preferentially Expressed Antigen in Melanoma (PRAME), the cancer-testis antigen NY-ESO-1, and survivin, with potential antineoplastic activity. Donor derived T-cells are mixed, ex vivo, with protein fragments derived from the TAAs WT1, PRAME, NY-ESO-1, and survivin. Upon intravenous administration, the donor-derived WT1/PRAME/NY-ESO-1/Survivin-specific T-lymphocytes recognize and kill cancer cells expressing these TAAs. WT1, NY-ESO-1, PRAME, and survivin, are expressed on certain tumor cell types and play key role in tumor cell proliferation and survival.",
  "abbreviation": "multi-TAA-specific T cells",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/donor-derived-wt1-prame-ny-eso-1-survivin-specific-t-lymphocytes/"
}